Larotrectinib shows promise in paediatric patients with TRK gene mutations

A new cancer drug has proven safe and effective for pediatric patients with a rare tumour gene mutation. The study tested the safety and dose of larotrectinib (LOXO-195) in paediatric patients with a mutation known as tropomyosin receptor kinases (TRK) that can occur in a variety of tumour types.

Read more: https://www.europeanpharmaceuticalreview.com/news/74260/larotrectinib-trk-gene-mutations/